4//SEC Filing
Stewart Jeffrey Ryan 4
Accession 0001415889-25-004462
CIK 0001551152other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 5:00 PM ET
Size
15.2 KB
Accession
0001415889-25-004462
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Transactions
- Award
Option (Right to Buy)
2025-02-13+33,854→ 33,854 totalExercise: $192.86Exp: 2035-02-12→ Common Stock (33,854 underlying) - Award
Common Stock, $0.01 par value
2025-02-13+19,111→ 80,052 total - Award
Common Stock, $0.01 par value
2025-02-13+7,840→ 87,892 total - Award
Common Stock, $0.01 par value
2025-02-13+9,268→ 97,160 total - Award
Common Stock, $0.01 par value
2025-02-13+9,432→ 106,592 total
Holdings
- 1,338(indirect: By Trust)
Common Stock, $0.01 par value
Footnotes (6)
- [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
- [F5]The reporting person disclaims beneficial ownership of all securities held by his spouse.
- [F6]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 11,285 on February 13, 2026, 11,285 on February 13, 2027, and 11,284 on February 13, 2028.
Documents
Issuer
AbbVie Inc.
CIK 0001551152
Entity typeother
Related Parties
1- filerCIK 0001761675
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 5:00 PM ET
- Size
- 15.2 KB